Gilead Sciences, Inc.

Other

Orsobio, Inc.

The Liver Company Inc.

Joshua A Kaplan

William John Watkins

Barton W Phillips

Gary Bruce Phillips

Devan Naduthambi

Zhimin Du

Chandrasekar Venkataramani

Peiyuan Wang

Musong Kim

Juan A Guerrero

Kirk L Stevens

Stephane Perreault

Jennifer Anne Treiberg

Jerry B Evarts

Leena Patel

Lafe J Purvis, Ii

Shaopei Cai

Hyung-Jung Pyun

Scott E Lazerwith

Michael L Mitchell

Thorsten A Kirschberg

Rick Andrew Lee

Jinfa Du

Tetsuya Kobayashi

Jonathan William Medley

Suet Chung Yeung

Philip Anthony Morganelli

Neil H Squires

Jennifer R Lo

Joshua J Van Veldhuizen

Julie Farand

Kin Shing Yang

John Edward Knox, Jr

Marcin Stasiak

William Baker

Anna Zagorska

Josh Van Veldhuizen

Sophia L Shevick

Jeff A Zablocki

Scott A Mitchell

Gregory Notte

Zhongdong Zhao

Michael Sangi

David Sperandio

Jennifer Alissa Loyer-Drew

Brian P Bestvater

John E Knox, Jr

Megan E Neubig

Casey Lockwood Olen

Kevin S Currie

Peter A Blomgren

Jeffrey E Kropf

Petr Jansa

Christopher T Clark

Daniel H Byun

David Dornan

Doris T Tang

Zachary A Kasun

Morin Mae Frick

Susanna Y Stinson

Kirk K Stevens

Nathaniel H Stanley

Elizabeth M Horstman

James L Bachman

Stephane Perrault

Lafe J Ii Purvis

William J Watxins

Compounds of formula: wherein the variable substituents are defined herein.

KHK inhibitors

This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.

Substituted pyrrolizine compounds and uses thereof

Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives

The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (TLD), or chronic kidney disease (CKD).

LPA receptor antagonists and uses thereof

The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).

The present disclosure relates generally to compounds that bind to FXR and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

FXR (NR1H4) modulating compounds

Compounds having the following formula (I) and methods of their use and preparation are disclosed: 

Tank-binding kinase inhibitor compounds

The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein X, Y, Z, n, m', A&#x2032;, R, R, and Rare described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.

Phosphatidylinositol 3-kinase inhibitors

The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, or a mixture thereof, wherein n, m, q, A', W, W, W, R, R, and Rare described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.

Growing community of inventors

Foster City, CA, United States of America

Joshua A Kaplan